AtriCure Q3 2025 Financial Results and Outlook

AtriCure, Inc. reported its financial results for the third quarter of 2025, showing a 15.8% year-over-year increase in worldwide revenue to $134.3 million. The company also raised its financial outlook for the full year. Key highlights include a net loss improvement of $7.6 million to $0.3 million, adjusted EBITDA of $17.8 million, and $30.1 million in cash generated during the quarter. The company's U.S. revenue grew by 14.5% to $109.3 million, driven by strong sales across key product lines. International revenue increased by 22.0% to $25.0 million. AtriCure now projects full-year 2025 revenue to be between $532 million and $534 million, with adjusted EBITDA expected to be between $55 million and $57 million. The company will hold a conference call to discuss these results.